MedTrace Logo

Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome

NCT01737255 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2022-03-31

No results posted yet for this study

Summary

This study is aimed at exploring the use of whole body MRI for early cancer detection in TP53 mutation carriers and population controls, with the hypothesis that more cancers will be detected in the TP53 mutation carrier group. A secondary end-point will be the number of incidental findings detected and subsequent investigations required. A series of questionnaires will be used to assess the psychological impact of screening on both the study and control group.

Conditions

  • Li-Fraumeni Syndrome

Interventions

OTHER

Whole body MRI

Individuals will undergo whole body and brain MRI

OTHER

Psychological questionnaires

All recruits will complete questionnaires at 6 time points to assess psychological impact

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Institute of Cancer Research, United Kingdom

    lead OTHER

Principal Investigators

  • Rosalind Eeles, PhD · Institute of Cancer Research, Surrey, UK

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2016-09-30
Completion
2017-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01737255 on ClinicalTrials.gov